INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated  exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials.

“Based on how the EMACC was developed, we expected a robust correlation between EMACC and CDR when used side-by-side in a clinical trial, and this analysis, while confirming our hypothesis, also validates the selection of the cognitive endpoints measured in the AD02 trial,” said Judith Jaeger, Ph.D., an internationally recognized neuropsychologist and part of the team that partnered with biopharma to develop EMACC in 2017. “The CDR-SB was not designed to measure cognitive change in clinical trials; it was developed as a staging instrument and relies largely on subjective assessments. The EMACC, on the other hand, was empirically derived to measure cognitive change in early AD patients objectively. This high degree of precision offers a more accurate assessment of cognitive function.”

Key Findings

• Statistical Correlation: An independent review confirmed a highly significant correlation (p